Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

BI 425809 is a potent and selective glycine transporter 1 (GlyT1) inhibitor being developed for the treatment of cognitive impairment in Alzheimer disease and schizophrenia. Translational studies evaluated the effects of BI 425809 on glycine levels in rat and human cerebrospinal fluid (CSF). Oral ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenbrock, Holger, Desch, Michael, Kleiner, Oliver, Dorner‐Ciossek, Cornelia, Schmid, Bernhard, Keller, Sascha, Schlecker, Christina, Moschetti, Viktoria, Goetz, Sophia, Liesenfeld, Karl‐Heinz, Fillon, Gwenaelle, Giovannini, Riccardo, Ramael, Steven, Wunderlich, Glen, Wind, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226115/
https://www.ncbi.nlm.nih.gov/pubmed/30136756
http://dx.doi.org/10.1111/cts.12578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226115/
https://www.ncbi.nlm.nih.gov/pubmed/30136756
http://dx.doi.org/10.1111/cts.12578

Ejemplares similares